These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15695801)

  • 21. Does health economics have an impact on non-Hodgkin's lymphoma patients' options?
    Otte A
    Nucl Med Commun; 2008 Aug; 29(8):748-9. PubMed ID: 18753830
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
    Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
    Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bexxar, iodine I 131 tositumomab, effective in long-term follow-up of non-Hodgkin's lymphoma.
    Kaminski M
    Cancer Biol Ther; 2007 Jul; 6(7):996-7. PubMed ID: 19358342
    [No Abstract]   [Full Text] [Related]  

  • 24. How and why does radioimmunotherapy work?
    Macklis RM
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1269-71. PubMed ID: 15275708
    [No Abstract]   [Full Text] [Related]  

  • 25. Cure of incurable lymphoma.
    DeNardo GL; Sysko VV; DeNardo SJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S46-56. PubMed ID: 16979440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioimmunotherapy of non-Hodgkin's lymphomas.
    Cheson BD
    Curr Drug Targets; 2006 Oct; 7(10):1293-300. PubMed ID: 17073591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretargeted radioimmunotherapy (PRIT) using an antibody-streptavidin fusion protein in non-Hodgkin's lymphoma.
    Weiden PL
    Leuk Lymphoma; 2002 Oct; 43(10):1971-3. PubMed ID: 12481894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosimetry and radioimmunotherapy of non-Hodgkin's lymphoma.
    Postema EJ
    J Nucl Med; 2004 Dec; 45(12):2126-7; author reply 2127. PubMed ID: 15585492
    [No Abstract]   [Full Text] [Related]  

  • 29. Underestimation of absorbed dose to kidney.
    Postema EJ; Buijs WC; Boerman OC; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1707-8. PubMed ID: 14530491
    [No Abstract]   [Full Text] [Related]  

  • 30. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
    Ghobrial I; Witzig T
    Oncology (Williston Park); 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640. PubMed ID: 15209190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma.
    Hernandez MC; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1274-87. PubMed ID: 15275710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy.
    Hartmann Siantar CL; DeNardo GL; DeNardo SJ
    J Nucl Med; 2003 Aug; 44(8):1322-9. PubMed ID: 12902424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk?
    Otte A; Dierckx RA
    Nucl Med Commun; 2005 Dec; 26(12):1045-7. PubMed ID: 16264349
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.
    Gregory SA; Hohloch K; Gisselbrecht C; Tobinai K; Dreyling M
    Oncologist; 2009; 14 Suppl 2():4-16. PubMed ID: 19819920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody.
    Postema EJ; Oyen WJ; Boerman OC; Corstens FH
    J Nucl Med; 2003 May; 44(5):853. PubMed ID: 12732690
    [No Abstract]   [Full Text] [Related]  

  • 39. [Radioimmunotherapy with (90)Y-Ibritumomab tiuxetan].
    Brockmann H; Biersack HJ
    Dtsch Med Wochenschr; 2006 Mar; 131(9):438-40. PubMed ID: 16493567
    [No Abstract]   [Full Text] [Related]  

  • 40. Bias reduction in correlation of radiation-absorbed dose with response.
    Koral KF; Zasadny K; Wahl RL
    J Nucl Med; 2004 Jul; 45(7):1271; author reply 1271-2. PubMed ID: 15235076
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.